Verapamil: A Review of its Pharmacological Properties and Therapeutic Use in Coronary Artery Disease

Drugs

Volumn 51, Issue 5, 1996, Pages 792-819

  Brogden, Rex N ^a   Benfield, Paul ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINA;

BEPRIDIL; CALCIUM ANTAGONIST; METOPROLOL; NICARDIPINE; NIFEDIPINE; PROPRANOLOL; VERAPAMIL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANKLE EDEMA; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; HEADACHE; HEART REINFARCTION; HUMAN; HYPERTENSION; LETHARGY; MORTALITY; RASH; RESTENOSIS; REVIEW; SECONDARY PREVENTION; SUSTAINED RELEASE PREPARATION; VERTIGO;

ANGINA PECTORIS; ANIMALS; CALCIUM CHANNEL BLOCKERS; CORONARY DISEASE; HUMANS; MYOCARDIAL INFARCTION; VASODILATOR AGENTS; VERAPAMIL;

EID: 0029932046     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651050-00007     Document Type: Review

References (194)

1. Silke B, Verma SP, Nelson GI, et al. The effects on left ventricular performance of verapamil and metoprotol singly and together in exercise-induced angina pectoris. Am Heart J 1985 Jun; 109: 1286-93
2. Klein HO, Ninio R, Oren V, et al. The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment by equilibrium-gated radionudide ventriculography. Circulation 1983 Jan; 67: 101-10
3. Johnston DL, Gebhardt VA, Donald A, et al. Comparative effects of propranolol and verapamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina: a double-blind, placebo-controlled, randomized, crossover study with radionuclide ventriculography. Circulation 1983 Dec; 68: 1280-9
4. Chew CYC, Brown G, Singh BN, et al. Effects of verapamil on coronary hemodynamic function and vasomobility relative to its mechanism of antianginal action. Am J Cardiol 1983; 51: 699-705
5. Ferlinz J, Easthope J, Arnow WS. Effects of verapamil on myocardial performance in coronary disease. Circulation 1979; 59: 313-9
6. Vlietstra RF, Farias MAC, Frye RL, et al. Effect of verapamil on left ventricular function: a randomised placebo-controlled study. Am J Cardiol 1983; 51: 1213-7
7. Silke B, Verma SP, Nelson GI, et al. The effects on left ventricular performance of nifedipine and verapamil in exercise-induced angina pectoris. Br J Clin Pharmacol 1984 Jun; 17: 735-43
8. Myreng Y, Myhre E. Effects of verapamil on left ventricular relaxation and filling dynamics in coronary artery disease: a study by pulsed Doppler echocardiography [see comments]. Am Heart J 1989 Apr; 117: 870-5
9. Nishimura RA, Schwartz RS, Holmes JDR. Failure of calcium channel blockers to improve ventricular relaxation in humans. J Am Coll Cardiol 1993 Jan; 21: 182-8
10. Betocchi S, Piscione F, Perrone-Filardi P, et al. Effects of intravenous verapamil on left ventricular relaxation and filling in angina pectoris. Am J Cardiol 1990 Oct 1; 66: 818-25
11. Ahmed JH, Elliot HL, Meredith PA. Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects. Cardiovasc Drugs Ther 1992 Apr; 6: 153-8
12. Gill JB, Cairns JA, McEwan MP. Improved left ventricular performance during exercise with verapamil or nifedipine in patients with chronic stable angina. Am Heart J 1987 Mar; 113; 700-7
13. Sadick NN, Tan ATH, Fletcher PJ, et al. A double-blind randomised trial of propranolol and verapamil in the treatment of effort angina. Circulation 1982; 66 (3): 574-9
14. Théroux P, Taeymans Y, Waters DD. Calcium antagonists: clinical use in the treatment of angina. Drugs 1983; 25: 178-95
15. Ferlinz J, Turbow ME. Antianginal and myocardial metabolic properties of verapamil in coronary artery disease. Am J Cardiol 1982; 46: 1019-26
16. Rouleau J-L, Chatterjee K, Ports TA, et al. Mechanism of relief of pacing-induced angina with oral verapamil. Circulation 1983; 67: 94-100
17. Soward AL, Vanhaleweyk GL, Serruys PW. The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review. Drugs 1986 Jul; 32: 66-101
18. Brodsky SJ, Cutler SS, Weiner DA, et al. Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomised crossover study. Circulation 1982; 66(3): 569-74
19. Frishman WH, Klein NA, Strom JA, et al. Superiority of verapamil to propranolol in stable angina pectoris: a double-blind, randomised crossover trial. Circulation 1982; 65 (1 Pt 2): 51-9
20. De Divitiis O, Liguori V, Di Somma S, et al. Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil. Eur Heart J 1987 Dec; 8 Suppl M: 43-54
21. Rodrigues EA, Kohli RS, Hains AD, et al. Comparison of nicardipine and verapamil in the management of chronic stable angina. Int J Cardiol 1988 Mar; 18: 357-69
22. Bala Subramanian VB, Bowles MJ, Khurmi NS, et al. Evaluation of verapamil and high dose nifedipine in patients with chronic stable angina with objective methods. Acta Med Scand Suppl 1984; 681: 61-73
23. Sigurd B, Hansen JF. Verapamil or propranolol in the treatment of stable angina pectoris of effort. Acta Med Scand Suppl 1984; 681: 75-81
24. Lesbre JP, Lalau JD, Jaubourg ML, et al. Verapamil versus propranolol in stable effort angina. Randomized, crossed, double-blind study [in French]. Ann Cardiol Angeiol Paris 1988 Apr; 37: 205-10
25. Levantesi D, Marraccini P, Michelassi C. Elective response to propranolol or verapamil in ischemia on effort. Can J Cardiol 1989 Sep; 5: 299-304
26. Singh BN, Chey CYC, Josephson MA, et al. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil. Am J Cardiol 1982; 50: 886-93
27. Fleckenstein-Grün G, Frey M, Thimm F, et al. Differentiation between calcium- and cholesterol-dominated types of arteriosclerotic lesions: antiarteriosclerotic aspects of calcium antagonists. J Cardiovasc Pharmacol 1991; 18 Suppl 6: S1-9
28. Nayler WG. The molecular basis for the use of calcium antagonists in ischaemic heart disease. Drugs 1992; 43 Suppl. 1: 21-7
29. Nayler WG, Ferrari R, Williams A. Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial junction in the ischeamic and reperfused myocardium. Am J Cardiol 1980 Aug; 46: 242-8
30. Weinstein GS, Rao PS, Tyras DH. Reduction of myocardial injury with verapamil before aortic cross-clamping. Ann Thorac Surg 1990 Mar; 49: 419-23
31. Werner GS, Schmid M, Klein HH, et al. The cardioprotective effect of verapamil during percutaneous transluminal coronary angioplasty [in German]. Z Kardiol 1988 Nov; 77: 728-35
32. El-Khoury F, Maarek M, Jean M, et al. Electrocardiographic evaluation of the anti-ischemic effects of verapamil during angioplasty [in French]. Ann Cardiol Angeiol 1994 Jun; 43: 351-6
33. Bussmann WD, Seher W, Gruengras M. Reduction of creatine kinase and creatine kinase-MB indexes of infarct size by intravenous verapamil. Am J Cardiol 1984 Dec 1; 54: 1224-30
34. Kloner RA, Braunwald E. Effects of calcium antagonists on infarction myocardium. Am J Cardiol 1987 Jan 30; 59: 84B-94B
35. Heide RSV, Schwartz LM, Reimer KA. The novel calcium antagonist Ro 40-5967 limits myocardial infarct size in the dog. Cardiovasc Res 1994 Oct; 28: 1526-32
36. Sullivan AT, Baker DJ, Drew GM. Effect of calcium channel blocking agents on infarct size after ischaemia-reperfusion in anaesthetised pigs: relationship between cardioprotection and cardiodepression. J Cardiovasc Pharmacol 1991 May; 17: 707-17
37. Mrak RE, Carry MM, Murphy ML, et al. Reperfusion injury in ischemic myocardium: effects of nifedipine and verapamil. Am J Cardiovasc Pathol 1990; 3: 61-8
38. Richard V, Tron C, Blanc T, et al. Infarct size-limiting properties of Ro 40-5967, a novel nondihydropyridine calcium channel, in anesthetized rats: comparison with verapamil. J Cardiovasc Pharmacol 1995 Apr; 25: 552-7
39. Wolfe CL, Donnelly TJ, Sievers R, et al. Myocardial protection with verapamil during ischaemia and reperfusion: dissociation between myocardial salvage and the degree of ATP depletion during ischaemia. Cardiovasc Res 1991 Feb; 25: 101-9
40. Adachi T, Miura T, Noto T, et al. Does verapamil limit myocardial infarct size in a heart deficient in xanthine oxidase? Clin Exp Pharmacol Physiol 1990 Nov; 17: 769-79
41. Przyklenk K, Kloner RA. Effect of verapamil on postischemic 'stunned' myocardium: importance of the timing of treatment. J Am Coll Cardiol 1988 Mar; 11: 614-23
42. Reifart N, Marston W, Zierler MK, et al. Effects of bepridil on regional myocardial ischemia and comparison with verapamil. Am J Cardiol 1986 Sep 1; 58: 541-6
43. Tillmanns H, Neumann FJ, Parekh N, et al. Pharmacologic effects on coronary microvessels during myocardial ischaemia. Eur Heart J 1990 Apr; 11 Suppl. B: 10-5
44. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (first of two parts). N Engl J Med 1992; 326 (Jan 23): 242-50
45. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med 1992; 326 (Jan 30): 310-8
46. Bonebrake FC, Bertha B, Folts JD. Verapamil combined with aspirin for inhibiting epinephrine-stimulated platelet thrombus formation in stenosed canine coronary arteries. Coron Artery Dis 1991 Jun; 2: 487-92
47. McTavish D, Sorkin EM. Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 1989; 38 (1): 19-76
48. Schömig A, Rehmert G, Kurz T, et al. Calcium antagonism and norepinephrine release in myocardial ischemia. J Cardiovasc Pharmacol 1992; 20 Suppl. 7: 16-20
49. Wallén NH, Held C, Rehnqvist N, et al. Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. Am J Cardiol 1995 Jan 1; 75: 1-6
50. Rouleau JL, Chatterjee K, Parmley WW, et al. Myocardial catecholamine balance during angina: effects of calcium entry blockers, verapamil and nifedipmine. Am Heart J 1985 Feb; 109: 201-9
51. Swies J, Omoghai EKI, Smith GM. Occlusion and reperfusion-induced arrhythmias in rats: involvement of platelets and effects of calcium antagonists. J Cardiovasc Pharmacol 1990 May; 15: 816-25
52. Brocchieri A, Saporiti A, Pacchiarini L, et al. Activation of platelets by ADP, collagen or thrombin: effect of the calcium channel blocker verapamil [abstract no. 2089]. Thromb Haemost 1995; 73 (6): 1447
53. Walkowiak B, Koziolkiewicz W, Michalec L, et al. Changes in platelet response to ADP caused by verapamil [abstract no. 2097]. Thromb Haemost 1995; 73 (6): 1449
54. L-Lacoste L, Lam JYT, Hung J, et al. Oral verapamil inhibits platelet thrombus formation in humans. Circulation 1994 Feb; 89: 630-4
55. Górski J, Nowak J, Slonecka A, et al. Inhibition by verapamil of platelet membrane aggregation may protect patients with IHD and hypertension from atherosclerosis [abstract]. Atherosclerosis 1994 Sep 15; 109: 275
56. Gadzhiev A, Kubaliev A, Naumov V, et al. Effects of nifedipine, diltiazem and verapamil on platelet aggregation: comparative study in healthy donors and patients with congestive heart failure [abstract]. J Heart Fail 1993 May; 1 Suppl.: abstr.519
57. Orekhov AN, Baldenkov GN, Terlov VV, et al. Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, β-blockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol 1988; 12 Suppl. 6: 66-8
58. Blumlein SL, Sievers R, Kidd P, et al. Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit. Am J Cardiol 1984 Oct 1; 54: 884-9
59. Parmley WW. Vascular protection from atherosclerosis: potential of calcium antagonists. Am J Cardiol 1990 Dec 18; 66: 16-22
60. Strunge P, Engby B, Schmidt E, et al. Variation of serum lipoproteins in postmyocardial infarction patients treated with verapamil or placebo. Acta Med Scand Suppl 1984; 681: 53-7
61. Walldius G. Effect of verapamil on serum lipoproteins in patients with angina pectoris. Acta Med Scand Suppl. 1984; 681: 43-8
62. Barnes C, Hamilton PG, Lebel M. Effects of monotherapy with sustained-release verapamil on blood pressure, lipid levels, renal function, diabetic control, and patient well-being in patients with mild to moderate hypertension. Curr Ther Res 1993 Aug; 54: 127-41
63. Catalano M, Cislaghi C, Carzaniga G, et al. Effects of treatment with verapamil SR and captopril on the lipid profile of hypertensive patients. Drugs 1992; 44 Suppl. 1: 88-93
64. Lewis GRJ. Long-term results with verapamil in essential hypertension and its influence on serum lipids. Am J Cardiol 1986 Feb 26; 57: 35D-8D
65. Fleckenstein-Grün G, Thimm F, Frey M. Progression and regression by verapamil of vitamin D3-induced calcific medial degeneration in coronary arteries of rats. J Cardiovasc Pharmacol 1995 Aug; 26: 207-13
66. Conrad K, Barbee RW, Maymind M, et al. Verapamil decreases early signs of atherosclerosis more than captopril in the diabetic hypertensive rat [abstract]. Am J Hypertens 1993 May; 6: 41A
67. Xhu B-Q, Sievers RE, Isenberg WM, et al. Regression of atherosclerosis in cholesterol-fed rabbits: effects of fish oil and verapamil. J Am Coll Cardiol 1990 Jan; 15: 231-7
68. Orekhov AN, Pivovarova EM, Sobenin IA, et al. Use of cell culture for optimisation of direct antiatherogenic therapy with verapamil. Drugs 1992; 44 Suppl. 1: 105-10
69. Orekhov AN. In vitro models of anti-atherosclerotic effects of cardiovascular drugs. Am J Cardiol 1990 Dec 18; 66: 231-81
70. Orekhov AN, Tertov VV, Khashimov KA, et al. Antiatherosclerotic effects of verapamil in primary culture of human aortic intimal cells. J Hypertens 1986; 4 Suppl. 6: S153-5
71. Orekhov AN, Tertov VV, Lyakishev AA, et al. Use of cultured atherosclerotic cells for investigation of antiatherosclerotic effects of anipamil and other calcium antagonists. J Hum Hypertens 1991 Oct; 5: 425-30
72. Midtbo KA. Effects of long-term verapamil therapy on serum lipids and other metabolic parameters. Am J Cardiol 1990 Dec 18; 66: 13-5
73. Libretti A, Catalano M. Lipid profile during antihypertensive treatment. The SLIP Study Group. Drugs 1993; 46 Suppl. 2: 16-23
74. Held C, Hlemdahl P, Rehnqvist N, et al. Short-term treatment effects of metoprolol or verapamil on haemostatic markers, catecholamines and lipids in patients with stable angina pectoris. Eur Heart J 1995; 16 Abstract Supplement: 468
75. Husum D, Johnsen A, Jensen G. Requirements for drug monitoring of verapamil: experience from an unselected group of patients with cardiovascular disease. Pharmacol Toxicol 1990 Mar; 66: 163-9
76. Tartaglione TA, Pieper JA, Lopez LL, et al. Pharmacokinetics of verapamil and norverapamil during long-term oral therapy. Res Commun Chem Pathol Pharmacol 1983 Apr; 40: 15-27
77. Fuemnayor NT, Faggin BM, Cubeddu LX. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients. Drugs 1992; 44 Suppl. 1: 1-11
78. Jespersen CM, Frederiksen M, Hansen JF, et al. Circadian variation in the pharmacokinetics of verapamil. Eur J Clin Pharmacol 1989; 37: 613-5
79. Rumiantsev DO, Piotrovskii VK, Metelitsa VI, et al. Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy. Br J Clin Pharmacol 1989 Sep; 28: 357-61
80. John DN, Fort S, Lewis MJ. Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers. Br J Clin Pharmacol 1992 Jun; 33: 623-7
81. Schwartz JB. Aging alters verapamil elimination and dynamics: single dose and steady-state responses. J Pharmacol Exp Ther 1990 Oct: 255: 364-73
82. Somogyi A, Albrecht M, Kliems G, et al. Pharmacokinetics, bioavailablity and ECG response of vereapamil in patients with liver cirrhosis. Br J Clin Pharmacol 1981; 12: 51-60
83. Powell AC, Elliott SL, Horowitz JD. Verapamil in unstable angina pectoris: failure to demonstrate a relationship between efficacy and plasma levels. Ther Drug Monit 1988; 10: 34-8
84. Picca M, Azzollini F, Cereda A, et al. Comparison of the anti-anginal efficacy of four calcium antagonists and propranolol in stable angina pectoris. Eur J Clin Pharmacol 1989 Oct; 37: 325-31
85. Leon MB, Rosing DR, Lipson RO, et al. Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol 1981 July; 48: 131-8
86. Cutler NR, Anders RJ, Jhee SS, et al. Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am J Cardiol 1995 Jun 1; 75: 1102-6
87. Kohli RS, Rodrigues EA, Hughes LO, et al. Sustained release verapamil, a once daily preparation: objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina. J Am Coll Cardiol 1987 Mar; 9: 615-21
88. Vandenburg M, Dews I, Gibbs J, et al. Sustained release verapamil in chronic stable angina pectoris: a multicentre randomised double-blind crossover design trial vs placebo [abstract]. Br J Clin Pharmacol 1990 Aug; 30: 340-1
89. Miller AJ, Grais IM, Kaminsky LA. The long-term treatment of stable angina pectoris with verapamil. J Clin Pharmacol 1990 Oct; 30: 916-21
90. Acanfora D, De CL, Di PA, et al. Age-related changes of anti-anginal effects of verapamil in patients with stable effort angina. A medium term randomized double-blind placebo controlled trial. G Ital Cardiol 1993 May; 23: 451-8
91. Foale RA, Vandenburg MJ. Sustained-release verapamil and nifedipine in exercise-induced angina pectoris. Eur Heart J 1992 Feb; 13: 256-60
92. Winniford MD, Fulton KL, Corbett JR, et al. Propranolol-verapamil versus propranolol-nifedipine in severe angina pectoris of effort: a randomized, double-blind, crossover study. Am J Cardiol 1985 Feb 1; 55: 281-5
93. Lablanche JM, Gommeaux A, Fourrier JL, et al. Cross-over double-blind study of verapamil versus diltiazem in effort myocardial ischemia [in French]. Ann Cardiol Angeiol Paris 1989 May; 38: 281-4
94. Nielsen HK, Krusell LR, Husted SE, et al. Bepridil versus verapamil in stable angina pectoris - a controlled clinical trial. Int J Cardiol 1989 Jun; 23: 357-64
95. Matteoli S, Trappolini M, Galli V, et al. Bepridil in stable angina of effort: a double-blind comparison with verapamil [in Italian]. Cardiologia 1988 Apr; 33: 413-8
96. Eichstaedt H, Danne O, Raab E, et al. Comparative measurements of gallopamil and verapamil in the treatment of ischaemic heart disease. Acta Ther 1990 Jan; 16: 29-41
97. Molinero E, Salcedo A, Sagastagoitia JD, et al. Treatment of transient myocardial ischemia in patients with stable angina: a comparative study of verapamil slow-release and nifedipine plus propranolol. J Cardiovasc Pharmacol 1992 Apr; 19: 650-3
98. Winniford MD, Huxley RL, Hillis LD. Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients with severe angina of effort. J Am Coll Cardiol 1983 Feb; 1 (2 Pt 1): 492-8
99. Silber S, Vogler A, Theisen K. Equal anti-ischemic properties of isosorbide dinitrate plus verapamil and isosorbide dinitrate plus propranolol. A randomized, double-blind and crossover study. Z Kardiol 1986; 75 Suppl 3: 100-5
100. Lessem J. Combined therapy with Ca-antagonists and beta-adrenergic receptor blocking agents in chronic stable angina. Acta Med Scand Suppl 1984; 681: 83-90
101. Findlay IN, MacLeod K, Gillen G, et al. A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris. Br Heart J 1987 Apr; 57: 336-43
102. Bowles MJ, Bala-Subramanian V, Davies AB, et al. Double-blind randomized crossover trial of verapamil and propranolol in chronic stable angina. Am Heart J 1983 Dec; 106: 1297-306
103. Johnson SM, Mauritson DR, Corbett JR, et al. Double-blind randomised, placebo-controlled comparison of propranolol and verapamil in the treatment of patinets with stable angina pectoris. Am J Med 1981 September; 71: 443-51
104. Hopkinson ND, Hui KP, Smith MP. A comparison of sustained release verapamil versus atenolol for 24 h protection from exercise-induced angina pectoris. Eur Heart J 1991 Dec; 12: 1273-7
105. Forslund L, Björkander I, Ericksson S, et al. Effects of metoprolol or verapamil treatment on results from exercise testing and long-term electrocardiogram recordings in stable angina pectoris. Short-term results from the APSIS study. Eur Heart J 1995; 16 Abstract Supplement: 422
106. Friedensohn A, Meshulam R, Schlesinger Z. Randomized double-blind comparison of the effects of isosorbide dinitrate retard, verapamil sustained-release, and their combination on myocardial ischemic episodes. Cardiology 1991; 79 Suppl. 2: 31-40
107. Schneider W, Maul FD, Bussmann WD, et al. Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment. Eur Heart J 1988 Feb; 9: 149-58
108. Jespersen CM, Klitgaard NA, Nielsen H, et al. Sustained-release and instant-release verapamil in treatment of angina pectoris. Eur J Clin Pharmacol 1989; 36: 625-7
109. Pellinen TJ, Lukkala K, Sundberg S, et al. Efficacy of conventional and sustained-release verapamil in stable angina pectoris. Ann Med 1992; 24: 49-53
110. Tan AT, Quek S. Verapamil administered twice daily in stable angina pectoris. Chest 1984 Jan; 85: 55-8
111. Weiner DA, Klein MD, Cutler SS. Efficacy of sustained-release verapamil in chronic stable angina pectoris. Am J Cardiol 1987 Feb 1; 59: 215-8
112. Weiner DA, McCabe CH, Cutler SS, et al. Efficacy and safety of verapamil in patients with angina peetoris after 1 year of continuous, high-dose therapy. Am J Cardiol 1983 May 1; 51: 1251-5
113. Zanolla L, Trevi GP, Rizzo A, et al. Long-term persistence of antianginal effect of oral verapamil in chronic stable angina. J Cardiovasc Pharmacol 1984 May-Jun; 6: 423-8
114. Parodi O, Simonetti I, L'Abbate A, et al. Verapamil versus propranolol for angina at rest. Am J Cardiol 1982 October; 50: 923-8
115. Parodi O, Simonetti I, Michelassi C, et al. Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit. Am J Cardiol 1986 Apr 15; 57: 899-906
116. Capucci A, Bassein L, Bracchetti D, et al. Propranolol v. verapamil in the treatment of unstable angina. A double-blind cross-over study. Eur Heart J 1983 Mar; 4: 148-54
117. Rizzon P, Scrutinio D, Mangini SG, et al. Randomized placebo-controlled comparative study of nifedipine, verapamil and isosorbide dinitrate in the treatment of angina at rest. Eur Heart J 1986 Jan; 7: 67-76
118. Singh N, Mironov D, Goodman S, et al. Treatment of silent ischemia in unstable angina: a randomized comparison of sustained-release verapamil versus metoprolol [abstract]. J Am Coll Cardiol 1995 (special issue): 88-9
119. Maresta A, Marzocchi A, Capucci A, et al. Nifedipine compared with verapamil in unstable angina pectoris. Int J Clin Pharmacol Res 1986; 6: 291-301
120. The Israeli Sprint Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomised intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988; 9: 354-64
121. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988 Aug 18; 319 (7): 385-92
122. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and stable angina: an overview. BMJ 1989 Nov 11; 299: 1187-92
123. Lichtlen PR, Hugenholtz PG, Rafflenbuel W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Anti-atherosclerotic Therapy (INTACT). Lancet 1990 May 12; 335: 1109-11
124. Held PH, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 1993 Oct; 14 Suppl. F: 18-25
125. Boden WE, Krone RJ, Kleiger RE, et al. Electrocardiographic subset analysis of diltiazem administration on long term outcome after acute myocardial infarction. Am J Cardiol 1991 [Feb 15; 67 (5): 335-42
126. Hansen JF. Secondary prevention with calcium antagonists after acute myocardial infarction. Drugs 1992; 44 Suppl 1: 33-43
127. Persson S. Calcium antagonists in secondary prevention after myocardial infarction. Drugs 1991; 42 Suppl. 2: 54-60
128. Danish SG on V in MI. Verapamil in acute myocardial infarction. Am J Cardiol 1984; 54: 24-8
129. Danish SG on V in MI. Verapamil in acute myocardial infarction. Eur Heart J 1984; 5: 516-28
130. Danish SG on V in MI. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990 Oct 1; 66: 779-85
131. Hansen JF. Treatment with verapamil after an acute myocardial infarction. Review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II). Drugs 1991; 42 Suppl 2: 43-53
132. Danish SG on V in MI. Treatment with verapamil after an acute myocardial infarction: a review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II). Cardiovasc Rev Rep 1993 May; 14: 32-42
133. Hansen JF et al. Treatment with verapamil during and after an acute myocardial infarction: a review based on the Danish Verapamil Infarction Trials I and II. J Cardiovasc Pharmacol 1991; 18 Suppl. 6: 20-5
134. Danish SG on V in MI. Secondary prevention of death and reinfarction with verapamil after an acute myocardial infarction. J Hum Hypertens 1990 Dec; 4 Suppl. 5: 19-25
135. Hansen JF. Review of postinfarct treatment with verapamil: combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1994 Aug; 8 Suppl. 3: 543-7
136. Jespersen CM, Fischer HJ, Spange ML. The prognostic significance of post-infarction angina pectoris and the effect of verapamil on the incidence of angina pectoris and prognosis. Eur Heart J 1994 Feb; 15: 270-6
137. Vaage-Nilsen M, Rasmussen V, Holländer NH. Prevalence of transient myocardial ischaemia during the first year after a myocardial infarction. Effect of treatment with verapamil. Eur Heart J 1992 May; 13: 666-70
138. Anderson LT, Sigurd B, Fischer Hansen J, et al. Verapamil and arcadian variation of sudden cardiac death. Am Heart J In press
139. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 1-7
140. Rehnqvist N, Hjemdahl P, Billing E, et al. Prevention of cardiac events in patients with angina pectoris: results of the APSIS study [abstract]. Eur Heart J 1995 Aug; 16 Suppl. H: 18
141. Liu MW, Roubin GS, King SB. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989; 79: 1374-87
142. Kober G, Vallbracht C, Kadel C, et al. Results of repeat angiography up to eight years following percutaneous transluminal angioplasty. Eur Heart J 1989; 10 Suppl. G: 49-53
143. Stein O, Halperin G, Stein Y. Long term effects of verapamil on aortic smooth muscle cells cultured in the presence of hyper-cholesterolemic serum. Arteriosclerosis 1987; 7: 585-92
144. Block LH, Emmons LR, Vogt E, et al. Calcium channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle. Med Sci 1989; 86: 2388-92
145. Hoberg E, Dietz R, Frees U, et al. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br Heart J 1994 Mar; 71: 254-60
146. Bentivoglio LG, Leo LR, Wolf, NM, et al. Frequency and importance of unprovoked coronary artery spasm in patients with angina pectoris undergoing percutaneous transluminal coronary angioplasty. Am J Cardiol 1983; 51: 1067-71
147. Dorros G, Cowley MJ, Simpson J, et al. Persutaneous transluminal coronary angioplasty: report of complications from the National heart. Lung, and Blood Institute PTCA Registry. Circulation 1983; 67: 723-30
148. Babbitt DG, Perry JM, Forman MB. Intracoronary verapamil for reversal of refractory coronary vasospasm during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1988 Nov; 12: 1377-81
149. Pomerantz RM, Kuntz RE, Diver DJ, et al. Intracoronary verapamil for the treatment of distal microvascular coronary artery spasm following PTCA. Cathet Cardiovasc Diagn 1991 Dec; 24: 283-5
150. Piana RN, Paik GY, Cohen DJ, et al. Intracoronary verapamil for 'no reflow' following PTCA [abstract 3160]. Circulation 1993; 88 (4 pt 2): 1-587
151. Danish SG on V in MI. Secondary prevention with verapamil after myocardial infarction. Am J Cardiol 1990 Dec 18; 66: 33-40
152. Arstall MA, Beltrame JF, Mohan P, et al. Incidence of adverse events during treatment with verapamil for suspected acute myocardial infarction. Am J Cardiol 1992 Dec 15; 70: 1611-2
153. McGourty JC, Silas JH, Solomon SA. Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapy. Postgrad Med J 1985 Mar; 61: 229-32
154. Gonski PN. Stevens-Johnson syndrome induced by verapamil. Med J Aust 1992 May 4; 156: 672
155. Lin AYF, Baker BA. Verapamil-associated Stevens-Johnson syndrome. Drug Intell Clin Pharm 1989 Dec; 23: 987-8
156. Kurkcuoglu N, Alaybeyi F. Erythema multiforme after verapamil treatment. J Am Acad Dermatol 1991 Mar; 24: 511-2
157. Drenth JPH, Michiels JJ, Van JT. Verapamil-induced secondary erythermalgia. Br J Dermatol 1992 Sep; 127: 292-4
158. Pritza DR, Bierman MH, Hammeke MD. Acute toxic effects of sustained-release verapamil in chronic renal failure. Arch Intern Med 1991 Oct; 151: 2081-4
159. Psaty B. Calcium antagonists: a new study warns of adverse effects. Case-control study presented at the American Heart Association Conference on Cardiovascular disease. Epidemiology and Prevention, San Antonio, Texas. March 1995. Inpharma 1995 Mar 25: No.979: 3-5
160. Verapamil meta-analysis sponsored by Searle suggests "no evidence of harm": case control study condradicts Psaty conclusion of higher MI risk with CCBs. FDC Rep Pink Sheet 1996 Jan 29: 6
161. Watling SM, Crain JL, Edwards TD. Verapamil overdose: case report and review of the literature. Ann Pharmacother 1992 Nov; 26: 1373-8
162. Horowitz BZ, Rhee KJ. Massive verapamil ingestion. Am J Emerg Med 1989 Nov; 7: 624-31
163. Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med 1993 Oct; 95: 431-8
164. Lip GYH, Ferner RE. Poisoning with anti-hypertensive drugs: calcium antagonists. J Hum Hypertens 1995 Mar; 9: 155-61
165. Rosansky SJ. Verapamil toxicity - treatment with hemoperfusion. Ann Intern Med 1991 Feb 15; 114: 340-1
166. Shah AR, Passalacqua BR. Case report: sustained-release verapamil overdose causing stroke: an unusual complication. Am J Med Sci 1992 Dec; 304: 357-9
167. Sporer KA, Manning JJ. Massive ingestion of sustained-release verapamil with a concretion and bowel infarction. Ann Emerg Med 1993 Mar; 22: 603-5
168. Doering W. Effect of coadministration of verapamil and quinidine on serum digoxin clearance. Eur J Clin Pharmacol 1983; 25: 517-21
169. Pedersen KE, Christiansen BD, Kjaer K, et al. Verapamil-induced changes in digoxin kinetics and intraerythrocytic sodium concentration. Clin Pharmacol Ther 1983; 34: 8-13
170. Rodin SM, Johnson BF, Wilson J, et al. Comparative effects of verapammil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther 1988; 43: 668-72
171. Hedman A, Angelin B, Arvidsson A, et al. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 1991 Mar; 49: 256-62
172. Klein HO, Kaplinsky E. Verapamil and digoxin: their respective effects on atrial fibrillation and their interaction. Am J Cardiol 1982; 50: 894-902
173. Guerrero JR, Martin SS. Verapamil: full specrtum calcium channel blocking agent: an overview. Med Res Rev 1984; 4: 87-109
174. McGoon MD, Vlietstra RE, Holmes DR, et al. The clinical use of verapamil. Mayo Clin Proc 1982; 57: 495-510
175. Kuhlmann J. Effects of quinidine, verapamil and nifedipine on the pharmacokinetics and pharmacodynamics of digitoxin during steady state conditions. Arzneimittelforschung 1987; 37: 545-8
176. Baky SH, Singh BN. Verapamil hydrochloride: pharmacological properties and the role in cardiovascular therapies. Pharmacotherapy 1982; 2: 328-53
177. Findlay IN, Dargie HJ, Gillen G, et al. Effects on cardiac function, heart rate amd blood pressure during combination therapy with verapamil and atenolol. Br J Clin Pharmacol 1985; 19: 565-6
178. Hutchinson SJ, Lorimeer AR, Lakhdar A, et al. β-Blockers and verapamil: a cautionary tale. BMJ 1984; 289: 659-60
179. Johnston DL, Lesoway R, Humen DP, et al. Clinical and haemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomised cross-over study. Am J Cardiol 1985; 55: 680-7
180. Epstein SE, Rosing DR. Verapamil:its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981; 64: 437-41
181. Maisel AS, Motulsky HJ, Insel PA. Hypotension after quinidine plus verapamil. Possible additive competition at alpha-adrenergic receptors. N Engl J Med 1985 Jan 17; 312: 167-70
182. Smith MS, Benyunes MC, Bjornsson TD, et al. The influence of cimetidine on the pharmacokinetics and the pharmacodynamics of verapamil. J Am Coll Cardiol 1984; 3: 568
183. Barbarash RA. Verapamil-rifampin interaction. Drug Intell Clin Pharm 1985; 19: 559-60
184. Barbarash RA, Bauman JL, Fischer JH, et al. Near-total reduction in verapamil bioavailability by rifiamin. Chest 1988; 94: 954-9
185. Mooy J, Böhm R, Van Baak M, et al. The influence of antituberculosis drugs on the plasma level of verapamil. Eur J Clin Pharmacol 1987; 32: 107-9
186. MacPhee GJA, McInnes GT, Agnew E, et al. Clinically relevant adverse interaction between verapamil and carbamazepine in epileptic patients. Br J Clin Pharmacol 1986; 21: 569-70
187. Kishore K, Raina A, Misra V. Acute verapamil toxicity in a patient with chronic toxicity: possible interaction with ceftriaxone and clindamycin. Ann Pharmacother 1993 Jul-Aug; 27: 877-80
188. Schulte-Sasse U, Hess W, Markschies-Hornung A, et al. Combined effects of halothane anesthesia and verapamil on systemic hemodynamics and left ventricular myocardial contractility in patients with ischemic heart disease. Anesth Analg 1984 Sep; 63: 791-8
189. Buss J, Lasserre JJ, Heene DL. Asystole and cardiogenic shock due to combined treatment with verapamil and flecainide. Lancet 1992 Aug 29; 340: 546
190. Gillis JC, Wagstaff AJ, Goa KL. Alteplase: a reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Drugs 1995 Jul; 50 (1): 102-36
191. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981 April 2; 304 (14): 801-7
192. Hansteen V, Moinichen E, Lorensten E, et al. One year's treatment with propranolol after myocardial nninfarction: preliminary report of Norwegian Multicentre Trial. BMJ 1982; 284: 155-60
193. Olsson G, Rehnqvist N, Sjögren A, et al. Long term treatment with metoprolol after myocardial infarction. Effect on 3 year mortality and morbidily. J Am Coll Cardiol 1985; 5: 1428-37
194. Zannad F. Calcium antagonists: are they useful as additive therapy to thrombolysis in acute myocardial infarction? Drugs Today 1993; 29 Suppl. A: 19-25